Philippe Moreau
#91,009
Most Influential Person Now
French hematology scientist
Philippe Moreau's AcademicInfluence.com Rankings
Philippe Moreaumedical Degrees
Medical
#954
World Rank
#1229
Historical Rank
Hematology
#10
World Rank
#11
Historical Rank
Download Badge
Medical
Philippe Moreau's Degrees
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Philippe Moreau Influential?
(Suggest an Edit or Addition)Philippe Moreau's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (2005) (1202)
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) (1104)
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. (2015) (1072)
- Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. (2012) (1017)
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. (2007) (879)
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. (2011) (877)
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) (812)
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (2015) (809)
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (2017) (776)
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma (2014) (743)
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. (2014) (703)
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. (2013) (684)
- Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. (2014) (666)
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. (2016) (662)
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006) (662)
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) (586)
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) (555)
- The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. (1981) (544)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (524)
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (2010) (523)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (2019) (520)
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 (2005) (491)
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. (2017) (441)
- HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. (1998) (440)
- Proteasome inhibitors in multiple myeloma: 10 years later. (2012) (438)
- IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. (1999) (424)
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (423)
- Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). (2010) (413)
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (409)
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (2011) (406)
- Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. (2009) (392)
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (2019) (388)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (378)
- The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. (2003) (369)
- HLA-G: from biology to clinical benefits. (2008) (362)
- Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. (2017) (360)
- HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. (2003) (356)
- Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. (2008) (355)
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. (2006) (355)
- Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. (2006) (354)
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. (2019) (346)
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma (2018) (327)
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. (2017) (320)
- Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. (2001) (319)
- International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
- Beyond the increasing complexity of the immunomodulatory HLA-G molecule. (2008) (318)
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. (2002) (314)
- Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival (2005) (311)
- Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association (2010) (306)
- Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
- Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
- HLA-G: An Immune Checkpoint Molecule. (2015) (287)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. (2012) (285)
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. (2011) (285)
- Chemotherapy‐driven dysbiosis in the intestinal microbiome (2015) (280)
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (2018) (279)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (279)
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2018) (266)
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. (2011) (261)
- Prognostic significance of copy-number alterations in multiple myeloma. (2009) (261)
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. (2017) (259)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
- Frontline therapy of multiple myeloma. (2015) (249)
- HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? (2005) (247)
- The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. (2006) (246)
- High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. (2007) (245)
- Expression of HLA-G in human cornea, an immune-privileged tissue. (2003) (243)
- Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. (2014) (241)
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
- An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. (1994) (233)
- Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
- Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. (2013) (228)
- Trogocytosis‐based generation of suppressive NK cells (2007) (228)
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma (2013) (226)
- The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement (2007) (222)
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients (1998) (222)
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. (2017) (217)
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (2013) (216)
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. (2016) (214)
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. (2017) (202)
- Prognostic role of circulating exosomal miRNAs in multiple myeloma. (2017) (202)
- Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia (2012) (198)
- Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
- HLA-G: a shield against inflammatory aggression. (2001) (193)
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group (2016) (189)
- The genetic structure of 3′untranslated region of the HLA-G gene: polymorphisms and haplotypes (2010) (186)
- Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. (2020) (184)
- Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. (2012) (176)
- Polymorphic Sites at the 3’ Untranslated Region of the HLA-G Gene Are Associated with Differential hla-g Soluble Levels in the Brazilian and French Population (2013) (174)
- Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease (2001) (173)
- Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells (1999) (172)
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project (2013) (172)
- Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. (2016) (172)
- Autologous hematopoietic stem-cell transplantation for multiple myeloma. (2009) (171)
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. (2003) (169)
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX (2018) (167)
- Current treatment landscape for relapsed and/or refractory multiple myeloma (2015) (166)
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations (2010) (164)
- Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. (2009) (163)
- Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study. (2008) (161)
- International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. (2010) (161)
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. (2020) (160)
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (2010) (157)
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (156)
- Genomic landscape and chronological reconstruction of driver events in multiple myeloma (2018) (153)
- HLA-G gene repression is reversed by demethylation (2003) (152)
- Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel (2018) (152)
- Biology and functions of human leukocyte antigen-G in health and sickness. (2003) (152)
- Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. (2010) (149)
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone (2010) (146)
- Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry (1997) (146)
- Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. (2014) (144)
- A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. (2011) (143)
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
- In silico analysis of microRNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. (2009) (142)
- Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. (2016) (138)
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma (2010) (137)
- HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. (2000) (136)
- CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia (2002) (136)
- Genomic patterns of progression in smoldering multiple myeloma (2018) (135)
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting (2018) (133)
- Transcriptional and Posttranscriptional Regulations of the HLA-G Gene (2014) (133)
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. (2015) (132)
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study (2020) (131)
- Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. (2001) (130)
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. (2020) (129)
- Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection (2016) (129)
- How I treat extramedullary myeloma. (2016) (129)
- Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma (2012) (128)
- BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics (2015) (127)
- Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. (2011) (126)
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. (2009) (125)
- Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. (1992) (125)
- PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. (2014) (125)
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? (2011) (124)
- Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma (2008) (123)
- Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. (2005) (121)
- Genetic mapping of Ph-2, a single locus controlling partial resistance to Phytophthora infestans in tomato (1998) (119)
- Panobinostat for the Treatment of Multiple Myeloma (2015) (119)
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial (2020) (117)
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. (2011) (116)
- Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? (2009) (116)
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth (2017) (115)
- Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) (2015) (115)
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. (2016) (113)
- Modulation of HLA-G Expression in Human Neural Cells after Neurotropic Viral Infections (2005) (113)
- Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. (1996) (113)
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. (2016) (113)
- Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) (112)
- HLA-G in cancer: a way to turn off the immune system. (2003) (112)
- ABT-737 is highly effective against molecular subgroups of multiple myeloma. (2011) (111)
- Minor clone provides a reservoir for relapse in multiple myeloma (2013) (109)
- Hypoxia modulates HLA-G gene expression in tumor cells. (2007) (108)
- Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. (2000) (108)
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. (2018) (108)
- Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma (2008) (108)
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years (2015) (108)
- Long-term complications of total body irradiation in adults. (2001) (107)
- Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. (2008) (107)
- HLA-G and HLA-E: fundamental and Pathophysiological aspects. (2000) (106)
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. (2016) (104)
- 16S rRNA Gene Pyrosequencing Reveals Shift in Patient Faecal Microbiota During High-Dose Chemotherapy as Conditioning Regimen for Bone Marrow Transplantation (2014) (103)
- Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. (2007) (103)
- Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference (2016) (101)
- Non-classical transcriptional regulation of HLA-G: an update (2009) (100)
- Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. (1997) (100)
- Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. (2015) (100)
- The Dual Role of HLA-G in Cancer (2014) (100)
- High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience (1998) (99)
- Soluble HLA-G molecule. An alternatively spliced HLA-G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. (1995) (99)
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) (2020) (98)
- HLA-G Gene Polymorphism in Human Placentas: Possible Association of G*0106 Allele with Preeclampsia and Miscarriage (2008) (98)
- Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. (2019) (98)
- Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. (2010) (98)
- t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma (2003) (97)
- French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance (1998) (96)
- Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. (2013) (96)
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups (2017) (94)
- Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group (2010) (94)
- Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. (2006) (94)
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? (2015) (94)
- Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. (2001) (94)
- Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. (2010) (94)
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. (2020) (93)
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial (2019) (92)
- European perspective on multiple myeloma treatment strategies in 2014. (2014) (92)
- Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma (1999) (91)
- Targeting Bcl-2 for the treatment of multiple myeloma (2018) (91)
- Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021) (91)
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (91)
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (2021) (90)
- Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. (2012) (90)
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial (2021) (89)
- Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. (2017) (88)
- Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials (2007) (86)
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). (2002) (85)
- Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. (2003) (85)
- Viridans streptococcal bacteraemia in patients with neutropenia (1995) (85)
- Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial (2008) (85)
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. (2015) (85)
- VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. (2007) (84)
- Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. (2016) (83)
- Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients (2002) (83)
- Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma. (2019) (83)
- Tumour lysis syndrome and acute kidney injury in high‐risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco‐Hématologique (2013) (83)
- Modulation of HLA-G expression in human thymic and amniotic epithelial cells. (2000) (82)
- Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients (2012) (81)
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (81)
- Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. (2010) (79)
- HLA‐G in Transplantation: A Relevant Molecule for Inhibition of Graft Rejection? (2003) (79)
- A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma (2000) (79)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. (2018) (78)
- Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. (2001) (78)
- Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. (2019) (78)
- European perspective on multiple myeloma treatment strategies: update following recent congresses. (2012) (77)
- Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. (2004) (76)
- Timing the initiation of multiple myeloma (2019) (76)
- Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents (2012) (75)
- Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. (2010) (74)
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. (2020) (73)
- Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537) (2015) (73)
- CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. (2005) (72)
- Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. (1999) (71)
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. (2016) (70)
- Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma (2012) (70)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
- Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone (2015) (68)
- Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. (1998) (68)
- RREB-1 Is a Transcriptional Repressor of HLA-G1 (2009) (68)
- Worldwide genetic variation at the 3′ untranslated region of the HLA-G gene: balancing selection influencing genetic diversity (2013) (68)
- Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. (2007) (68)
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. (2021) (67)
- Teclistamab in Relapsed or Refractory Multiple Myeloma. (2022) (67)
- Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies (2013) (67)
- Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. (2006) (67)
- Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (2011) (66)
- Lenalidomide maintenance after transplantation for myeloma. (2010) (66)
- Research on HLA-G: an update. (2007) (65)
- A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis (2014) (64)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (64)
- Significant impact of survivin on myeloma cell growth (2007) (64)
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma (2015) (64)
- 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma (2013) (64)
- Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial (2015) (63)
- Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. (2016) (63)
- How I treat myeloma with new agents. (2017) (62)
- The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases (2015) (62)
- Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. (2012) (61)
- Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01. (2007) (61)
- Immunohistochemical Study of HLA‐G Expression in Lung Transplant Recipients (2009) (61)
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. (2016) (61)
- Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). (2016) (61)
- HLA-G expression in human melanoma cells: protection from NK cytolysis. (1999) (60)
- Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) (2013) (60)
- Long‐term outcome of monoclonal (type 1) cryoglobulinemia (2014) (60)
- Epstein–Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation (1999) (59)
- Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets (2014) (59)
- Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
- Good clinical practice recommendations for the use of PET/CT in oncology (2019) (59)
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. (2013) (58)
- FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma (2008) (58)
- Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2011) (58)
- Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study (2016) (58)
- Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial (2013) (58)
- Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. (2000) (58)
- Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. (1999) (58)
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents (2011) (58)
- Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. (2013) (58)
- HLA-G*0105N Null Allele Encodes Functional HLA-G Isoforms1 (2005) (58)
- HLA‐G gene activation in tumor cells involves cis‐acting epigenetic changes (2005) (58)
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study (2016) (58)
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) (58)
- Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. (2016) (57)
- The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape (2021) (57)
- CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. (2008) (57)
- Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. (2000) (57)
- Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. (2013) (57)
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
- Switch of HLA‐G alternative splicing in a melanoma cell line causes loss of HLA‐G1 expression and sensitivity to NK lysis (2005) (57)
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma (2013) (56)
- Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. (2021) (56)
- Monoclonal antibody therapy in multiple myeloma (2017) (56)
- Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. (2018) (56)
- Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study (2017) (56)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (56)
- 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. (2011) (56)
- Lack of CD27 in myeloma delineates different presentation and outcome (2006) (55)
- Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma (2014) (55)
- Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. (2012) (55)
- MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs (2013) (54)
- Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. (2016) (54)
- Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. (2019) (54)
- Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) (2020) (54)
- BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. (2018) (53)
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients (2012) (53)
- Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT (2014) (53)
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome (2019) (53)
- The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. (2012) (53)
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study (2017) (53)
- The effects of bortezomib on bone disease in patients with multiple myeloma (2014) (53)
- MicroRNAs targeting the immunomodulatory HLA-G gene: a new survey searching for microRNAs with potential to regulate HLA-G. (2015) (53)
- Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment (2017) (53)
- Thalidomide in patients with advanced multiple myeloma. (2000) (53)
- Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA) (2018) (52)
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (2011) (52)
- Cretaceous and Tertiary Palynomorph Assemblages from Banks Island and Adjacent Areas (N.W.T.) (1976) (52)
- Analysis of the role of HLA-G in preeclampsia. (2000) (52)
- Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. (1997) (52)
- Revealing the impact of structural variants in multiple myeloma. (2020) (51)
- Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
- Transformation of rat embryo fibroblasts by cloned polyoma virus DNA fragments containing only part of the early region. (1980) (51)
- Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study (2019) (50)
- Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection (1993) (50)
- High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. (1996) (50)
- G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma (1996) (50)
- Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. (2020) (49)
- Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR (2016) (49)
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
- HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus (2009) (49)
- Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial (2020) (49)
- Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (48)
- The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction (2011) (48)
- Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. (2015) (48)
- Liver HLA‐G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection (2011) (48)
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. (2018) (48)
- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide (2019) (47)
- Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2 (2016) (47)
- Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (2017) (46)
- Daratumumab for the treatment of multiple myeloma (2017) (46)
- p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. (2017) (46)
- Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma (2015) (46)
- How to manage neutropenia in multiple myeloma. (2012) (45)
- Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. (2016) (45)
- Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. (2019) (44)
- Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma (2015) (44)
- Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B (2004) (44)
- Rituximab in CD20 positive multiple myeloma (2007) (44)
- A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results (2012) (44)
- Increased Th17/Treg ratio in chronic liver GVHD (2014) (44)
- Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma (2020) (43)
- Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program (2012) (43)
- HLA-G 3' UTR-2 haplotype is associated with Human African trypanosomiasis susceptibility. (2013) (43)
- IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop (2008) (43)
- Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 (2017) (43)
- A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial (2018) (43)
- Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program (2012) (43)
- A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma (2017) (43)
- Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial (2017) (43)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
- Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. (2019) (42)
- A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 (2009) (42)
- Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. (2016) (42)
- ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY (2020) (42)
- Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia (2017) (42)
- Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-κB inducers (2006) (42)
- CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages (2019) (41)
- Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. (1997) (41)
- Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma (2019) (41)
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials (2020) (41)
- Characterization of HLA-G1, -G2, -G3, and -G4 isoforms transfected in a human melanoma cell line. (2001) (41)
- Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study (2012) (41)
- Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. (2015) (41)
- Multiple myeloma: from front-line to relapsed therapies. (2015) (41)
- Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Kr (2016) (41)
- BH 3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH 3 mimetics (2019) (41)
- Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma (2018) (40)
- Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions (2017) (40)
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
- Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial (2010) (39)
- Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study (2019) (39)
- How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? (2017) (39)
- Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. (2019) (39)
- HLA-G expression: immune privilege for tumour cells? (1999) (39)
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (39)
- Crucial role of the third and fourth hypervariable regions of HLA-DPB1 allelic sequences in the mixed lymphocyte reaction. (1992) (39)
- High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial. (2009) (39)
- Pharmacokinetics of high-dose melphalan in adults: influence of renal function. (1994) (39)
- Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. (2015) (38)
- Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux (2017) (38)
- Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study (2016) (38)
- Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. (2015) (38)
- Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2014) (37)
- Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14) (2017) (37)
- Linking Two Immuno-Suppressive Molecules: Indoleamine 2,3 Dioxygenase Can Modify HLA-G Cell-Surface Expression1 (2005) (37)
- Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. (2009) (37)
- Lenalidomide: a new therapy for multiple myeloma. (2008) (37)
- Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. (2005) (37)
- Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma (2017) (37)
- Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (36)
- Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group (2018) (36)
- Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma (2004) (36)
- Haplotypes of the HLA-G 3’ Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially (2017) (36)
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab (2021) (36)
- HLA-DP and allogeneic bone marrow transplantation. (1994) (35)
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (35)
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis (2020) (35)
- Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma (2018) (35)
- Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM) (2009) (35)
- Deciphering the chronology of copy number alterations in Multiple Myeloma (2019) (35)
- Association of HLA-G 3'UTR polymorphisms with response to malaria infection: a first insight. (2013) (35)
- Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial (2014) (35)
- IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma (2014) (35)
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. (2021) (34)
- Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone (2016) (34)
- An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma (2014) (34)
- Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2019) (34)
- Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi‐centre retrospective cohort study (2011) (34)
- Worldwide HLA-E nucleotide and haplotype variability reveals a conserved gene for coding and 3' untranslated regions. (2014) (34)
- High plasma levels of HLA-G are associated with low birth weight and with an increased risk of malaria in infancy (2014) (34)
- Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. (2014) (34)
- Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). (2005) (34)
- Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) (2017) (34)
- Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma (2010) (33)
- Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866) (2015) (33)
- A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity (1996) (33)
- HLA-G Expression in the Skin of Patients with Systemic Sclerosis (2009) (33)
- Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL) (2018) (33)
- Insights on Multiple Myeloma Treatment Strategies (2018) (33)
- Evidence for the presence of the alternatively spliced HLA-G mRNA forms in human mononuclear cells from peripheral blood and umbilical cord blood. (1995) (33)
- Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study (1998) (33)
- Expressed fusion gene landscape and its impact in multiple myeloma (2017) (32)
- The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials. (2006) (32)
- Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up (2015) (32)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (32)
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) (32)
- HLA-G gene transcriptional regulation in trophoblasts and blood cells: differential binding of nuclear factors to a regulatory element located 1.1 kb from exon 1. (1997) (32)
- High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. (2005) (32)
- Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. (2015) (32)
- Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. (2010) (32)
- A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). (2012) (32)
- Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial (2015) (32)
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
- Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. (2016) (31)
- Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients (2014) (31)
- Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study (2015) (31)
- HLA-G protein processing and transport to the cell surface (2002) (31)
- The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients (2012) (31)
- Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO) (2016) (31)
- Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes (2020) (30)
- Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study (2017) (30)
- Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis. (2004) (30)
- Study on Essential Derivation in Maize: III. Selection and Evaluation of a Panel of Single Nucleotide Polymorphism Loci for Use in European and North American Germplasm (2015) (30)
- Ovarian transposition by laparoscopy before radiotherapy in the treatment of hodgkin's disease (1998) (30)
- Severe chronic primary neutropenia in adults: report on a series of 108 patients. (2015) (30)
- Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. (2013) (30)
- Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR (2021) (30)
- Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials (2016) (29)
- Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study (2018) (29)
- A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia (2012) (29)
- Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study (2010) (29)
- Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution (2016) (29)
- A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2019) (29)
- Association of HLA-G 3' untranslated region polymorphisms with antibody response against Plasmodium falciparum antigens: preliminary results. (2013) (29)
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (2014) (29)
- Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry (1998) (29)
- BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma (2010) (29)
- A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. (2018) (29)
- Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. (2012) (28)
- Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients. (2020) (28)
- IgM myeloma: A multicenter retrospective study of 134 patients (2017) (28)
- Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study (2010) (28)
- Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (2021) (28)
- Viewpoint on the Functionality of the Human Leukocyte Antigen-G Null Allele at the Fetal-Maternal Interface (2002) (28)
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. (2020) (28)
- Simian virus 40 late promoter region able to initiate simian virus 40 early gene transcription in the absence of the simian virus 40 origin sequence (1984) (28)
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma (2015) (28)
- Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial (2007) (28)
- Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways (2018) (27)
- Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. (2017) (27)
- Human leukocyte antigen-G 3' untranslated region polymorphisms are associated with better kidney allograft acceptance. (2012) (27)
- Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. (1999) (27)
- Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1, (2011) (27)
- HLA-G and HLA-E: fundamental and pathophysiological aspects. (2000) (27)
- Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial (2014) (27)
- Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group (2020) (27)
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) (2021) (27)
- High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02 (2011) (26)
- Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma. (2007) (26)
- Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study (2019) (26)
- Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma (2017) (26)
- Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial (2015) (26)
- 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study (2014) (26)
- Multiple myeloma—translation of trial results into reality (2016) (26)
- The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. (2015) (26)
- Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. (2017) (26)
- Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. (2006) (26)
- Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (2021) (26)
- Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma (2019) (26)
- Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells (2013) (26)
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) (26)
- Prevalence of the reversed halo sign in neutropenic patients compared with non‐neutropenic patients: Data from a single‐centre study involving 27 patients with pulmonary mucormycosis (2003‐2016) (2017) (26)
- Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. (2009) (26)
- Hypoxic culture conditions for Mesenchymal Stromal/Stem Cells from Wharton's jelly: a critical parameter to consider in a therapeutic context. (2014) (26)
- Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins (2017) (25)
- Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). (2019) (25)
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (2014) (25)
- Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. (2014) (25)
- Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective (2019) (25)
- Non-classical HLA-E gene variability in Brazilians: a nearly invariable locus surrounded by the most variable genes in the human genome. (2012) (25)
- Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup (2015) (25)
- Interest of Pet Imaging in Multiple Myeloma (2019) (25)
- In vivo, RFX5 binds differently to the human leucocyte antigen‐E, ‐F, and ‐G gene promoters and participates in HLA class I protein expression in a cell type‐dependent manner (2004) (25)
- Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (2016) (24)
- Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma (2015) (24)
- Report of the 6th International Workshop on PET in lymphoma (2017) (24)
- Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM) (2013) (24)
- Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program (2011) (24)
- PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients (2017) (24)
- Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. (2019) (24)
- Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients (2011) (24)
- Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G (2014) (24)
- Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients (2021) (24)
- Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma (2019) (24)
- A highly virulent variant of HIV-1 circulating in the Netherlands (2022) (23)
- A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma (2013) (23)
- Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. (2020) (23)
- Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials (2020) (23)
- Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. (2011) (23)
- Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02) (2017) (23)
- Deacetylase inhibitors: an advance in myeloma therapy? (2017) (23)
- A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). (2011) (23)
- Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. (2006) (23)
- Isolated Richter's syndrome of the brain: two recent cases. (1994) (23)
- T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study (2019) (23)
- Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. (2017) (23)
- Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14) (2013) (23)
- Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma (2016) (23)
- Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes (2016) (22)
- Insights on the HLA-G evolutionary history provided by a nearby Alu insertion. (2013) (22)
- Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis. (2016) (22)
- Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse (2020) (22)
- ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2015) (22)
- Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant (2018) (22)
- Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO) (2020) (22)
- BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma (2017) (22)
- Soluble human leukocyte antigen -G during pregnancy and infancy in Benin: Mother/child resemblance and association with the risk of malaria infection and low birth weight (2017) (22)
- Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. (2013) (22)
- Lack of efficacy of clarithromycin in advanced multiple myeloma (1999) (21)
- Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study) (2019) (21)
- [Treatment of AL amyloidosis]. (2001) (21)
- Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. (2017) (21)
- Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity (2012) (21)
- Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials (2018) (21)
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. (2022) (21)
- Biochemical Characterization of the α-l-Rhamnosidase DtRha from Dictyoglomus thermophilum: Application to the Selective Derhamnosylation of Natural Flavonoids (2019) (21)
- Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) (2019) (21)
- Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system (2011) (21)
- Increased plasmacytoid dendritic cells and RORγt‐expressing immune effectors in cutaneous acute graft‐versus‐host disease (2013) (21)
- Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. (2013) (21)
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. (2021) (20)
- Cereblon expression in multiple myeloma: not ready for prime time (2013) (20)
- Extramedullary disease in multiple myeloma: a systematic literature review (2022) (20)
- Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations (2013) (20)
- RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway (2014) (20)
- Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma (2016) (20)
- Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes (2017) (20)
- Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. (2006) (20)
- Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome (2012) (20)
- Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy (2021) (20)
- Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial. (2009) (20)
- Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02 (2010) (20)
- Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results (2015) (20)
- Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation (2012) (20)
- ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). (2012) (20)
- Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients (2017) (20)
- Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other (2014) (19)
- Overall Survival in Spine Myeloma Metastases: Difficulties in Predicting With Prognostic Scores (2017) (19)
- New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib (2017) (19)
- Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials (2017) (19)
- Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial (2015) (19)
- MRD in multiple myeloma: more questions than answers? (2017) (19)
- Autologous stem cell transplantation for AL amyloidosis: a standard therapy? (1999) (19)
- Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infection. (2012) (19)
- Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups (2014) (19)
- Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial (2015) (19)
- Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. (2012) (18)
- Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor (2018) (18)
- Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. (2011) (18)
- Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. (2021) (18)
- Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant (2021) (18)
- Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis (2017) (18)
- The emerging role of carfilzomib combination therapy in the management of multiple myeloma (2014) (18)
- Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study (2018) (18)
- Reactive plasmacytoses can mimick plasma cell leukemia: Therapeutical implications (2007) (18)
- Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. (2009) (18)
- CD130 rather than CD126 expression is associated with disease activity in multiple myeloma (1999) (18)
- Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux (2016) (18)
- Association of HLA-G 3' untranslated region variants with type 1 diabetes mellitus. (2016) (18)
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus (2022) (17)
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM) (2016) (17)
- Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life (2020) (17)
- Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma (2016) (17)
- Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. (2013) (17)
- New developments in conditioning regimens before auto-SCT in multiple myeloma (2011) (17)
- Clinical ef fi cacy and management of monoclonal antibodies targeting CD 38 and SLAMF 7 in multiple myeloma (2016) (17)
- Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study (2010) (17)
- Influence of HLA-DP mismatches on primary MLR responses in unrelated HLA-A, B, DR, DQ, Dw identical pairs in allogeneic bone marrow transplantation. (1990) (17)
- Final Analysis of Overall Survival from the First Trial (2016) (17)
- Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma (2014) (17)
- "Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?". (2012) (17)
- The genetic diversity within the 1.4 kb HLA-G 5′ upstream regulatory region moderately impacts on cellular microenvironment responses (2018) (17)
- Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements (2018) (17)
- Patients with Systemic Sclerosis Present Increased DNA Damage Differentially Associated with DNA Repair Gene Polymorphisms (2014) (17)
- A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). (2019) (17)
- Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma (2011) (17)
- Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study (2010) (17)
- Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma (2013) (17)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study (2020) (17)
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA (2019) (17)
- Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study) (2016) (16)
- Death of frontline allo-SCT in myeloma. (2012) (16)
- The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma (2013) (16)
- Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma (2002) (16)
- Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies (2012) (16)
- Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. (2021) (16)
- Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases. (2006) (16)
- The X1 box of HLA-G promoter is a target site for RFX and Sp1 factors. (2000) (16)
- Erratum to: Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection (2016) (16)
- Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM) (2013) (16)
- Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update (2019) (16)
- Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT) (2013) (16)
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis (2020) (16)
- Lenalidomide Therapy in Nine Patients with POEMS Syndrome. (2009) (16)
- Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network (2019) (16)
- Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) (2018) (16)
- Logic programming reveals alteration of key transcription factors in multiple myeloma (2017) (16)
- Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) (2015) (16)
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (2012) (16)
- Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02). (2009) (16)
- Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report. (2011) (15)
- PET-CT in MM: a new definition of CR. (2011) (15)
- Human Leukocyte Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of Human African Trypanosomiasis. (2016) (15)
- Stem-cell transplantation in multiple myeloma. (2005) (15)
- Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma (2021) (15)
- Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma (2020) (15)
- Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide (2008) (15)
- Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. (2014) (15)
- A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma (2014) (15)
- Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial (2019) (15)
- Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma (2019) (15)
- Successful pregnancy after allogeneic bone marrow transplantation following conditioning including a 10-Gy single exposure total body irradiation. (1996) (15)
- Role of HLA-G in innate immunity through direct activation of NF-kappaB in natural killer cells. (2008) (15)
- Newly Diagnosed Myeloma in 2020. (2020) (15)
- Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas (2013) (15)
- Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results (2015) (15)
- Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial (2018) (14)
- The Autoimmune Regulator (Aire) transactivates HLA‐G gene expression in thymic epithelial cells (2019) (14)
- Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM (2018) (14)
- Safety of ixazomib for the treatment of multiple myeloma (2017) (14)
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial (2017) (14)
- Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. (1998) (14)
- Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning (2013) (14)
- Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study (2020) (14)
- Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment (2015) (14)
- Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. (2015) (14)
- Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients? (2012) (14)
- Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? (2011) (14)
- Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010) (2014) (14)
- A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma (2010) (14)
- High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma (2020) (14)
- Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience (2011) (14)
- Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study (2017) (14)
- Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses. (2017) (14)
- Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis (2019) (14)
- p53 regulates CD46 expression and measles virus infection in myeloma cells. (2018) (14)
- Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma (2020) (14)
- High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis (1995) (14)
- Multiple myeloma imaging. (2013) (14)
- Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study (2000) (13)
- The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective (2016) (13)
- PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma (2003) (13)
- Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
- TRISOMY 4 ASSOCIATED WITH ACUTE LYMPHOCYTIC LEUKAEMIA (1991) (13)
- Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study (2021) (13)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. (2020) (13)
- MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >75 YEARS WITH MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM01/01 (2008) (13)
- Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma (2017) (13)
- Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies (2018) (13)
- Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials (2020) (13)
- Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors (2010) (13)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (2010) (13)
- Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). (2013) (13)
- Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma (2012) (13)
- HLA‐G, ‐E and ‐F regulatory and coding region variability and haplotypes in the Beninese Toffin population sample (2018) (13)
- A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2011) (13)
- Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (2021) (13)
- Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. (1995) (13)
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis (2020) (13)
- High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma. (1993) (13)
- Oral therapy for multiple myeloma: ixazomib arriving soon. (2014) (13)
- First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma (2020) (12)
- HLA-G mRNA forms in human trophoblasts and peripheral blood lymphocytes: potential use in prenatal diagnosis. (1994) (12)
- Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy (2002) (12)
- Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma. (2020) (12)
- Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma (2018) (12)
- Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma (2017) (12)
- Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. (2016) (12)
- Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO). (2018) (12)
- ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS (2020) (12)
- Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (2016) (12)
- Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial (2019) (12)
- Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma (2020) (12)
- Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. (2020) (12)
- An original case of Francisella tularensis subsp. holarctica bacteremia after a near-drowning accident (2015) (12)
- Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma (2021) (12)
- Safety and efficacy of rituximab in steroid-refractory chronic GVHD (2013) (12)
- Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma (2010) (12)
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study (2019) (12)
- All transplantation-eligible patients with myeloma should receive ASCT in first response. (2014) (12)
- Multiple myeloma: so much progress, but so many unsolved questions (2013) (12)
- Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. (1996) (12)
- A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. (2020) (12)
- Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma. (2009) (12)
- [Alternative transcripts of the MHC of the non-classical class I HLA-G gene in the in trophoblast during the first pregnancy trimester and in the placenta at term]. (1995) (12)
- Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab (2016) (12)
- [Update of the recommendations of good clinical practice for the use of PET in oncology]. (2019) (12)
- Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES) (2019) (12)
- Mixed leukocyte culture reactivity, HLA-DP typing and GVHD. (1993) (12)
- Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors (2009) (12)
- Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. (2018) (12)
- Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (2019) (12)
- Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1 (2018) (11)
- Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia (2020) (11)
- Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. (1993) (11)
- Evolving role of stem cell transplantation in multiple myeloma. (2005) (11)
- Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study (2018) (11)
- The role of SLAMF7 in multiple myeloma: impact on therapy (2017) (11)
- The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma (2019) (11)
- Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. (2016) (11)
- Evolution of the levels of human leukocyte antigen G (HLA-G) in Beninese infant during the first year of life in a malaria endemic area: using latent class analysis (2016) (11)
- Autologous bone marrow transplantation for cyclosporin-related lymphoma in a renal transplant patient. (1994) (11)
- Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas (2017) (11)
- Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS (2018) (11)
- Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. (2019) (11)
- Modeling of experts’ divergent prior beliefs for a sequential phase III clinical trial (2013) (11)
- Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. (2019) (11)
- Frontline treatment of multiple myeloma in elderly patients. (2008) (11)
- Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients (2019) (11)
- 1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients (2012) (11)
- Natural killer cells are the unique lymphocyte cell subset which do not express HLA-G. (1995) (11)
- Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials (2019) (11)
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome ( (2017) (11)
- Differential Transcript Profiles of MHC Class Ib(Qa-1, Qa-2, and Qa-10) and Aire Genes during the Ontogeny of Thymus and Other Tissues (2014) (11)
- Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. (2013) (11)
- Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study (2019) (11)
- Role of the HLA-G immune checkpoint molecule in pregnancy. (2021) (10)
- Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. (2022) (10)
- Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (2015) (10)
- Abstract CT320: An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma (2015) (10)
- Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation (2014) (10)
- Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response (2021) (10)
- Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL (2008) (10)
- PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
- A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials. (2005) (10)
- Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial (2013) (10)
- Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults. (2017) (10)
- Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (2016) (10)
- Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience (2016) (10)
- Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials (2020) (10)
- Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma (2016) (10)
- Supporting the Return to Work of Breast Cancer Survivors: From a Theoretical to a Clinical Perspective (2022) (10)
- First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma (2019) (10)
- A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients (2018) (10)
- Crucial role of the third and fourth hypervariable regions of HLA-DPB1 allelic sequences in primary mixed-lymphocyte reaction: application in allogeneic bone marrow transplantation. (1993) (10)
- Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES (2013) (10)
- ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy. (2016) (10)
- S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (2019) (10)
- Human Leucocyte Antigen-G (HLA-G) and Its Murine Functional Homolog Qa2 in the Trypanosoma cruzi Infection (2015) (9)
- PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY (2019) (9)
- Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results. (2021) (9)
- Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2018) (9)
- High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy (2019) (9)
- Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome. (2007) (9)
- Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2017) (9)
- Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS) (2016) (9)
- MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) (2013) (9)
- Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT (2014) (9)
- Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866) (2015) (9)
- Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma (2020) (9)
- Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) (2018) (9)
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk (2021) (9)
- Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) (2015) (9)
- PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. (2011) (9)
- FDG-PET in the evaluation of myeloma in 2012. (2013) (9)
- Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX (2020) (9)
- Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study. (2016) (9)
- Upregulation of Soluble HLA‐G5 and HLA‐G6 Isoforms in the Milder Histopathological Stages of Helicobacter pylori Infection: A Role for Subverting Immune Responses? (2016) (9)
- Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
- Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK (2014) (9)
- Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs (2009) (9)
- Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. (2000) (9)
- Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM) (2013) (8)
- Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma (2018) (8)
- FLT3 ligand plasma levels in acute myeloid leukemia (2019) (8)
- Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma (2015) (8)
- Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. (2021) (8)
- Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation (2016) (8)
- FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma. (2007) (8)
- Ixazomib in the management of relapsed multiple myeloma. (2018) (8)
- Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients (2015) (8)
- Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). (2021) (8)
- Are the Immune Properties of Mesenchymal Stem Cells from Wharton’s Jelly Maintained during Chondrogenic Differentiation? (2020) (8)
- Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation (2010) (8)
- Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (2014) (8)
- Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta‐Refractory Myeloma (penta‐MM): MM‐255 (2018) (8)
- Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma. (1996) (8)
- Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO) (2018) (8)
- Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy (2008) (8)
- Initial treatment of transplant-eligible patients in multiple myeloma (2014) (8)
- Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma (2020) (8)
- High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial (2010) (8)
- Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial (2012) (8)
- Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis (2021) (8)
- Absence of the HLA-G*0113N allele in Amerindian populations from the Brazilian Amazon region. (2010) (8)
- Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. (2019) (8)
- Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial (2016) (8)
- Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF. (2000) (8)
- Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. (2016) (8)
- Identification, biochemical characterization, and in-vivo expression of the intracellular invertase BfrA from the pathogenic parasite Leishmania major. (2015) (8)
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (8)
- Pomalidomide in the management of relapsed multiple myeloma. (2016) (8)
- Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma. (1994) (8)
- Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk. (2019) (8)
- Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391). (2015) (8)
- Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux (2017) (8)
- B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (2022) (8)
- Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study (2018) (8)
- [Pseudallescheria boydii osteoarthritis in a patient with acute lymphoblastic leukemia: a case report]. (1999) (8)
- Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens (2008) (8)
- Initial treatment of transplant candidates with multiple myeloma. (2013) (8)
- Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM). (2019) (7)
- Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial (2012) (7)
- Cellular co-localization of intron-4 containing mRNA and HLA-G soluble protein in melanoma analyzed by fluorescence in situ hybridization. (2007) (7)
- Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma (2020) (7)
- Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (2011) (7)
- Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial (2010) (7)
- Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma (2010) (7)
- Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma (2019) (7)
- Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients (2008) (7)
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis (2021) (7)
- Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. (2012) (7)
- Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. (2012) (7)
- Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy (2017) (7)
- Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation. (2014) (7)
- Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391) (2015) (7)
- A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study. (2005) (7)
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas (2019) (7)
- Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. (2020) (7)
- Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 (2021) (7)
- Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM (2021) (7)
- Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. (2002) (7)
- A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2014) (7)
- Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1 (2020) (7)
- Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study (2021) (7)
- Increased soluble human leukocyte antigen-G levels in peripheral blood from climbers on Mount Everest. (2010) (7)
- Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma (2012) (7)
- Long-term results of total abdominopelvic irradiation in non-Hodgkin's lymphomas after failure of chemotherapy. (1998) (7)
- c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma (2020) (7)
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma (2021) (7)
- O95 Treatment of advanced multiple myeloma (MM) with thalidomide (THAL). Long term follow-up in a prospective study of 121 patients (2003) (7)
- Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. (2012) (7)
- Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study (2014) (7)
- [Primary granulocytic sarcoma of the pancreas: efficacy of early treatment with intensive chemotherapy]. (1996) (7)
- Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM) (2016) (7)
- Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. (2014) (7)
- A Prospective Phase II Trial of Lenalidomide and Dexamethasone (Len-Dex) in POEMS Syndrome (2015) (6)
- Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients. (2012) (6)
- MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age) (2013) (6)
- Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study (2014) (6)
- Pharmacological inhibition of DNA repair enzymes differentially modulates telomerase activity and apoptosis in two human leukaemia cell lines (2004) (6)
- [Invasive aspergillosis in intensive care]. (1995) (6)
- ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)--Identifying responders by subset analysis. (2016) (6)
- Stem cell transplantation in multiple myeloma. (2007) (6)
- Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis (2021) (6)
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics (2011) (6)
- Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options (2021) (6)
- LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy. (2021) (6)
- DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX) (2017) (6)
- Simple partial status epilepticus and antiglycolipid IgM antibodies: possible epilepsy of autoimmune origin. (1997) (6)
- Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial (2012) (6)
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial (2022) (6)
- Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial (2019) (6)
- Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. (2016) (6)
- Adjuvant Chemotherapy in the Treatment of Solitary Bone Plasmacytoma (2016) (6)
- Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1. (2015) (6)
- VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) (2022) (6)
- New insights in the treatment of patients with solitary bone plasmacytoma (2019) (6)
- Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba (2019) (6)
- 997PDSplit dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM) (2017) (6)
- Extramedullary multiple myeloma: extraosseous relapse is extra “bad news,” but why? (2013) (6)
- T-cell redirecting bispecific antibodies in multiple myeloma: a revolution? (2022) (6)
- Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease (2013) (6)
- The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability (2020) (6)
- Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria (2018) (6)
- Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma. (2010) (6)
- Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses (2020) (6)
- Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial (2013) (6)
- Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma (2015) (6)
- Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. (2022) (6)
- A Prospective Phase II Trial of Lenalidomide and Dexamethasone ( LEN-DEX) in POEMS Syndrome (2014) (6)
- A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone (2017) (6)
- Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. (2019) (5)
- Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR (2020) (5)
- Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) (2015) (5)
- [HLA-G: immune tolerance in normal and pathological physiology]. (2002) (5)
- Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis (2019) (5)
- Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status (2020) (5)
- Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial (2018) (5)
- Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study (2017) (5)
- Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation (2015) (5)
- Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier (2017) (5)
- No survival improvement in patients with high‐risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades (2021) (5)
- Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile (2021) (5)
- Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). (2012) (5)
- Revealing the impact of recurrent and rare structural variants in multiple myeloma (2019) (5)
- Definition of organ involvement and treatment response in primary systemic amyloidosis (AL) (2004) (5)
- Genomic organization and nucleotide sequence of a long mosaic repetitive DNA in the mouse genome (2004) (5)
- HLA-G expression during hookworm infection in pregnant women. (2019) (5)
- PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY (2019) (5)
- S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY (2019) (5)
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. (2023) (5)
- Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (2022) (5)
- Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens (2021) (5)
- Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients (2014) (5)
- Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM). (2016) (5)
- Soluble HLA-G induces NF–кB activation in natural killer cells (2010) (5)
- Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods (2021) (5)
- LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL (2014) (5)
- Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study (2017) (5)
- Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? (2017) (5)
- Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases (2016) (5)
- Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma (2014) (5)
- The Attenuated Live Yellow Fever Virus 17D Infects the Thymus and Induces Thymic Transcriptional Modifications of Immunomodulatory Genes in C57BL/6 and BALB/C Mice (2015) (5)
- Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study (2021) (5)
- Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases. (1998) (5)
- Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma (2009) (5)
- Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies. (1994) (5)
- Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). (2015) (5)
- Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM). (2015) (5)
- A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia (2020) (5)
- Safety and ef fi cacy of pomalidomide plus low-dose dexamethasone in STRATUS ( MM-010 ) : a phase 3 b study in refractory multiple myeloma (2016) (5)
- Learned Deep Radiomics for Survival Analysis with Attention (2020) (5)
- Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis (2021) (5)
- The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial (2018) (5)
- FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients? (2020) (5)
- Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide (2020) (5)
- Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03 (2019) (5)
- FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT). (2015) (4)
- Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults (2014) (4)
- MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial (2020) (4)
- Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. (2016) (4)
- Panobinostat to revert bortezomib resistance. (2013) (4)
- Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients (2010) (4)
- Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant (2022) (4)
- Circulating exosomal microRNAs are critical prognostic markers independent of cytogenetics and International Staging System in Multiple Myeloma (2015) (4)
- ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004). (2012) (4)
- Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation (2017) (4)
- First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of th (2013) (4)
- Localized lnvasive Pulmonary Aspergillosis in Patients with Neutropenia (1993) (4)
- ImmunoPET in Multiple Myeloma—What? So What? Now What? (2020) (4)
- Regular Article LYMPHOID NEOPLASIA Microenvironment-dependent proliferation and mitochondrial priming loss in mantle cell lymphoma is overcome by anti-CD20 (2016) (4)
- Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? (2020) (4)
- Global Approaches in Myeloma: Critical Trials That May Change Practice. (2018) (4)
- Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment. (2009) (4)
- Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma (2016) (4)
- Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience (2012) (4)
- Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma (2020) (4)
- Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients. (2016) (4)
- [High-dose melphalan in patients with multiple myeloma]. (1999) (4)
- Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study (2020) (4)
- Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma (2020) (4)
- Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (2010) (4)
- Clinical and biological significance of microRNA profiling in patients with myeloma. (2009) (4)
- DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma (2020) (4)
- HLA-DPB and susceptibility to hodgkins disease (1993) (4)
- La domus Augusta et les formations de parenté à Rome (2005) (4)
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. (2017) (4)
- The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis? (2019) (4)
- Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. (2022) (4)
- Monoclonal antibodies as an addition to current myeloma therapy strategies (2020) (4)
- Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide (2018) (4)
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study (2021) (4)
- A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma (2021) (4)
- Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation (2017) (4)
- Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04. (2022) (4)
- Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). (2020) (4)
- Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group (2016) (4)
- Skin patch, polyneuropathy, and paraproteinemia. (2012) (4)
- Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1. (2016) (4)
- An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2015) (4)
- Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder. (2013) (4)
- Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study (2019) (4)
- Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391) (2015) (4)
- Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma (2010) (4)
- Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial (2014) (4)
- molecule Beyond the increasing complexity of the immunomodulatory HLA-G (2013) (4)
- Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma (2021) (4)
- PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: MM-003 SUBANALYSIS OF ELDERLY PATIENTS (> 65 AND > 70 YEARS OF AGE) (2014) (4)
- Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation (2020) (4)
- Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (2020) (4)
- Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies (2021) (4)
- Allografting or autografting for myeloma. (2007) (4)
- A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (2019) (4)
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics (2021) (4)
- Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA. (2020) (3)
- Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM (2016) (3)
- Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. (2011) (3)
- [Multiple bone myelomas]. (2006) (3)
- Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial (2022) (3)
- Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study (2020) (3)
- Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience (2020) (3)
- A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination with Melphalan and Dexamethasone in Subjects with Newly-Diagnosed Light-Chain (AL)-Amyloidosis. (2008) (3)
- Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization. (1994) (3)
- A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients. (2018) (3)
- Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. (2013) (3)
- Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon (2016) (3)
- Identification of two new HLA-G alleles, G*01:01:03:03 and G*01:01:21, in Brazilian individuals. (2012) (3)
- Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4 (2015) (3)
- PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY (2019) (3)
- Decade in review—haematological cancer: Advances in biology and therapy (2014) (3)
- Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease. (2012) (3)
- Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma (2018) (3)
- Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure (2014) (3)
- Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study (2021) (3)
- Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide (2020) (3)
- Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: Total Body Irradiation (TBI) Plus Cyclophosphamide (or Melphalan) Is Not Superior to BEAM, A Single Institution Experience (2010) (3)
- A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. (2012) (3)
- Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study (2015) (3)
- FDG PET in Multiple Myeloma (2019) (3)
- Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR. (2018) (3)
- Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone (2020) (3)
- 5-Azacytidine (AZA) Compared to Intensive Chemotherapy in Elderly Acute Myeloid Leukemia (AML) Patients: Results of a Retrospective Single Centre Matched Analysis, (2011) (3)
- OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa (2021) (3)
- [Acquired autoantibodies directed against human factor VIIIc. Treatment of 2 hemorrhagic accidents with porcine factor VIIIc]. (1993) (3)
- Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (2021) (3)
- Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1 (2022) (3)
- myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib, (2012) (3)
- Simple methods for the detection of HLA-G variants in coding and non-coding regions. (2012) (3)
- Light Chain Escape in Multiple Myeloma (2018) (3)
- Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo. (2009) (3)
- Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply. (2016) (3)
- Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study (2020) (3)
- Role of bone marrow transplantation in the disease pathway of myeloma. (2007) (3)
- Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA (2019) (3)
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study (2019) (3)
- Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. (2022) (3)
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study (2020) (3)
- A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial) (2016) (3)
- DHPG at CMV viremia after allogeneic bone marrow transplantation. Result over a four year period (1986-1990). (1991) (3)
- Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1 (2022) (3)
- Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study (2019) (3)
- Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study (2019) (3)
- Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. (2019) (3)
- A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (2020) (3)
- A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients (2016) (3)
- Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma. (2013) (3)
- S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL (2022) (3)
- Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment (2015) (3)
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA (2022) (3)
- P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial (2021) (3)
- Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis (2022) (3)
- HLA-G liver expression and HLA-G extended haplotypes are associated with chronic hepatitis C in HIV-negative and HIV-coinfected patients. (2020) (3)
- ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010) (2015) (3)
- S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA (2019) (3)
- Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX (2017) (3)
- Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon. (1995) (3)
- Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma (2019) (2)
- Designing universal visuotactile pictograms (2020) (2)
- A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (2016) (2)
- The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma (2015) (2)
- Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study (2022) (2)
- Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. (2020) (2)
- Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort (2021) (2)
- Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT), (2011) (2)
- Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival (2022) (2)
- Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. (2013) (2)
- Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM) (2019) (2)
- Atypical plasma cell leukemia mistaken for lymphocytosis on blood count. (2015) (2)
- Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS) (2017) (2)
- Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX). (2017) (2)
- CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (2014) (2)
- Chronic Infection, a Neglected Cause Of Development Of Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Myeloma (2013) (2)
- S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA (2019) (2)
- Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults (2017) (2)
- [HLA-G in organ transplantation]. (2004) (2)
- A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE) (2019) (2)
- Placental Malaria is Associated with Higher LILRB2 Expression in Monocyte Subsets and Lower Anti-Malarial IgG Antibodies During Infancy (2022) (2)
- VI. Autologous stem cell transplantation and maintenance therapy (2013) (2)
- Estimating direct costs of care for patients with relapsed or refractory multiple myeloma in french hospitals (2008) (2)
- Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment (2014) (2)
- Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response (2015) (2)
- Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma (2014) (2)
- OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT (2021) (2)
- High-Throughput Microrna Profiling in Patients with Waldenstrom’s Macroglobulinemia. (2008) (2)
- Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. (2019) (2)
- Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft (2020) (2)
- Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study (2022) (2)
- Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial (2016) (2)
- FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. (2019) (2)
- Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France (2016) (2)
- Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma (2009) (2)
- Agranulocytosis in patients with Diamond‐Blackfan anaemia (DBA) treated with deferiprone for post‐transfusion iron overload: A retrospective study of the French DBA cohort (2022) (2)
- Best therapy for primary amyloidosis, a not-yet-solved question. (2004) (2)
- French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry (2022) (2)
- Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study (2020) (2)
- Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial (2017) (2)
- Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells (2017) (2)
- Paving the way to precision medicine in multiple myeloma (2021) (2)
- Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment (2018) (2)
- The anti-BCMA Bispecific T-cell Engager (BiTE®) Molecule AMG 420 Induced MRD-Negative Complete Responses in R/R Multiple Myeloma in a FIH study (2019) (2)
- Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en RRespiratoire et Onco-H (2013) (2)
- Hevylite® to Monitor Response to Therapy in Multiple Myeloma (2014) (2)
- Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (2015) (2)
- RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation (2020) (2)
- Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study (2021) (2)
- Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial (2013) (2)
- Human Leukocyte Antigen-G Is Frequently Expressed in Glioblastoma and May Be Induced inVitro by Combined 5-Aza-2-Deoxycytidine and Interferon- Treatments (2)
- THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (2015) (2)
- Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study (2012) (2)
- Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. (2006) (2)
- Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient (2008) (2)
- Use of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma (2008) (2)
- Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study. (2010) (2)
- Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES) (2019) (2)
- TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma (2021) (2)
- The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma (2019) (2)
- Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial (2023) (2)
- ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. (2022) (2)
- Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death. (2018) (2)
- Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient (2016) (2)
- Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. (2022) (2)
- MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy (2022) (2)
- Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma (2014) (2)
- Prospective Comparison Of Five Viral Infections (HHV6, CMV, EBV, ADV, BKv) After Umbilical Cord Blood (UCB) Vs PBSC Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (allo-SCT) In Adults (2013) (2)
- Cancer Therapy: Preclinical ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2/Mcl-1 Profile and Synergizes with Other Antineoplastic Agents (2011) (2)
- Elotuzumab for the treatment of multiple myeloma. (2014) (2)
- The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma. (2014) (2)
- Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003) (2013) (2)
- Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. (2019) (2)
- A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2017) (2)
- Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells (2013) (2)
- Total Marrow Irradiation in Multiple Myeloma: The French Myeloma Group Experience (2020) (2)
- Analysis of FDG PET diffuse bone marrow uptake (BMU) and splenic uptake (SU) in staging of Hodgkin lymphoma (HL): A reflect of disease infiltration or just inflammation? (2009) (2)
- Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with papillary transitional cell carcinoma of the bladder (2010) (2)
- MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs (2010) (2)
- Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1 (2017) (2)
- A multinational observational study in multiple myeloma (preamble): initial results of treatment patterns (2014) (2)
- ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS (2021) (2)
- Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. (2021) (2)
- Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes (2020) (1)
- An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment (2022) (1)
- All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study (2022) (1)
- Response to: Interference of daratumumab on the serum protein electrophoresis (2017) (1)
- Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply. (2022) (1)
- TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells (2010) (1)
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis (2020) (1)
- Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies (2022) (1)
- Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03) (2019) (1)
- Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis (2021) (1)
- PB2146 SINGLE AGENT DARATUMUMAB IN VERY ADVANCED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SINGLE CENTER RETROSPECTIVE STUDY (2019) (1)
- Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study (2017) (1)
- Patient‐Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once‐Weekly versus Twice‐Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM): MM‐138 (2018) (1)
- Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM) (2019) (1)
- OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY (2015) (1)
- A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial (2022) (1)
- Expression Profile Signature to Predict Response to Bortezomib and Dexamethasone Combination Therapy in Newly-Diagnosed Myeloma: Moving towards Prospective Prediction (2008) (1)
- Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients (2014) (1)
- IgM Myeloma: A Multicenter Retrospective Study of 159 Patients (2016) (1)
- Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs (2011) (1)
- Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines (2018) (1)
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study (2022) (1)
- A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome (2019) (1)
- Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03. (2017) (1)
- Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor (2018) (1)
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study (2021) (1)
- of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report (2012) (1)
- PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (2019) (1)
- Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain (2013) (1)
- Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. (2022) (1)
- A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study (2018) (1)
- A Genome-Wide Association Study Identi fi es a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (1)
- Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation (2010) (1)
- Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study (2022) (1)
- An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival (2015) (1)
- Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2010) (1)
- A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2016) (1)
- Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment (2015) (1)
- New Data on Subcutaneous Bortezomib (2014) (1)
- Peripheral Neuropathy in the Cassiopeia Study (2020) (1)
- Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma (2019) (1)
- Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit (2022) (1)
- Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses (2018) (1)
- Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity (2007) (1)
- Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment (2022) (1)
- HLA-A, -B, -C and –DRB1 High Resolution Matching Can Improve Patient' Outcome After Double Umbilical Allogeneic Stem Cell Transplantation (allo-SCT) (2013) (1)
- LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy (2021) (1)
- Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation (2014) (1)
- MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients. (2006) (1)
- Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma (2014) (1)
- myeloma cells apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated (2011) (1)
- Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses. (2020) (1)
- Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (1)
- Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells (2019) (1)
- S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS (2019) (1)
- Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study (2020) (1)
- Phase III multicentric randomized study of quinine as a potential MDR reversing agent in acute leukemias: 107 (1994) (1)
- Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA (2010) (1)
- Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd (2013) (1)
- Comparing the Performance of Serum Free Light Chain Measurements with Urine Electrophoresis and Immunofixation for Monitoring and Assessing Response to Therapy in Patients with Multiple Myeloma (2014) (1)
- Non-classical transcriptional regulation of HLA-G: an update (2010) (1)
- Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial. (2015) (1)
- A Randomized Phase II Study Evaluating the Efficacy, Safety and Cost-Effectiveness of Pegfilgrastim and Filgrastim After High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Lymphoma and Myeloma (PALM Study). (2010) (1)
- Chronic Viral Infection, Virus-Specific Monoclonal Immunoglobulin, and Development of Plasma Cell Malignancy (2011) (1)
- Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. (2022) (1)
- CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy (2016) (1)
- Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (2021) (1)
- Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study (2021) (1)
- Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). (2022) (1)
- A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE) (2019) (1)
- No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients (2015) (1)
- Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset (2020) (1)
- Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma (2015) (1)
- Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification (2022) (1)
- Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study. (2020) (1)
- Emergence of Mucormycosis in Onco-Hematology after Prolonged Use of Voriconazole: Attention Required. (2004) (1)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study (2021) (1)
- Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study (2015) (1)
- An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Initial Assessment of Treatment Patterns in Patients with ≥6 Months Follow-up (2014) (1)
- Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study (2018) (1)
- PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE-MM3 STUDY (2019) (1)
- P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 (2022) (1)
- Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM). (2018) (1)
- Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study (2020) (1)
- MM-339: Effect of Lenalidomide (R) ± Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies (2020) (1)
- Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern (2016) (1)
- Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma (2022) (1)
- Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study (2020) (1)
- Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM) (2015) (1)
- RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort? (2021) (1)
- PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose? (2021) (1)
- Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone (2021) (1)
- Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma. (2009) (1)
- Upfront Allogeneic-Stem Cell Transplantation for Patients with Non-Localized Untreated Peripheral T-Cell Lymphoma: An Intention-to-Treat Analysis from a Single Center (2014) (1)
- An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma (2022) (1)
- Treatment of Relapsed/Refractory Patients with Multiple Myeloma (2018) (1)
- STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) (2015) (1)
- Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866) (2015) (1)
- Safety and Efficacy of Caspofungin as Preventive and Empirical Antifungal Treatment of Neutropenic Allografted Patients. (2004) (1)
- UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA (2022) (1)
- The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow (2017) (1)
- Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS) (2013) (1)
- Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). (2016) (1)
- P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 (2022) (1)
- Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas (2008) (1)
- Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis (2021) (1)
- Chromatin accessibility combined with enhancer clusters activation mediates heterogeneous response to dexamethasone in myeloma cells (2021) (1)
- The Oncolytic Measles Virus Preferentially Infects p53 Abnormal Myeloma Cells (2016) (1)
- Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial (2015) (1)
- Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation. (2013) (1)
- A multinational observational study in multiple myeloma (preamble): assessment of disease impact on work productivity and activity (2014) (1)
- Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma (2022) (1)
- Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) (2018) (1)
- High-dose chemotherapy followed by autologous stem-cell transplantation in liver-transplanted multiple myeloma patients: a report of two cases. (2009) (1)
- High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients. (2007) (1)
- Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. (2020) (1)
- UPDATED PROGRESSION-FREE SURVIVAL (PFS) AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE (ISA-KD) VS KD IN RELAPSED MULTIPLE MYELOMA (MM) (2022) (1)
- Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML) (2010) (1)
- Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose (2021) (1)
- Phase 1 study of the combination of escalated total marrow irradiation using helical Tomotherapy and fixed high-dose melphalan (140 mg/m²) followed by autologous stem cell transplantation at first relapse in multiple myeloma. (2022) (1)
- MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH (2014) (1)
- Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (1)
- Do you know your equine practice clients? (2012) (1)
- Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study (2021) (1)
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. (2022) (1)
- High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma (2010) (1)
- Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study (2020) (1)
- The EHA Research Roadmap: Malignant Lymphoid Diseases (2022) (1)
- Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W. (2018) (1)
- Extended 5‐Year Follow‐Up of the Phase 3 ELOQUENT‐2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM): MM‐271 (2018) (1)
- Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation (2015) (1)
- Polyclonal Immunoglobulin Recovery is Enhanced After Autologous Stem Cell Transplant and Associates with Improved Clinical Outcomes in Multiple Myeloma Patients (2017) (1)
- S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS (2022) (1)
- Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results (2022) (1)
- A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009). (2012) (1)
- [Fusaria infection in patients with neutropenia: apropos of 3 cases]. (1996) (1)
- Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1 (2022) (1)
- DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6) (2022) (1)
- Frontline induction therapy for multiple myeloma (MM) in real-world clinical practice: Third interim analysis of the multinational, observational EMMOS study (NCT01241396) (2015) (1)
- RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study (2022) (1)
- (IFM) myeloma: a phase 2 study of the Intergroupe Francophone du Myélome autologous stem cell transplantation in patients with de novo multiple Bortezomib and high-dose melphalan as conditioning regimen before (2013) (0)
- Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients (2021) (0)
- DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myeloma (2019) (0)
- Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma (2021) (0)
- Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study (2021) (0)
- 87-P: HLA-E Varyability in the Brazilian Population (2010) (0)
- Increased Th17/Treg Ratio In Liver Chronic Graft-Versus-Host-Disease (2013) (0)
- Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study (2018) (0)
- Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group (2018) (0)
- Josine Blok, Peter Mason éds, Sexual asymmetry. Studies in Ancient Society, Amsterdam, J. C. Gieben, 1987, IX-298 p., 15 fig. (1990) (0)
- S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (0)
- Cost-effectiveness of posaconazole in the prophylaxis of invasive fungal infections in the French setting (2008) (0)
- Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. (2022) (0)
- LILRB1 and LILRB2 expression in peripheral blood immune cells at 18 and 24 months of age in infants born from mothers with placental malaria (2021) (0)
- Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) (2015) (0)
- Transcripts of MHC class I gene HLA-G and their applications. (1994) (0)
- Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial (2021) (0)
- First Line Treatment with the R-VAD+C Regimen Followed by ASCT for Patients under 65 with a Mantle Cell Lymphoma (MCL). From the GOELAMS Group. (2006) (0)
- Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution (2013) (0)
- Ancestim (r-metHuSCF) Plus Filgrastim for the Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplant after Failure of Prior Mobilization: The French Experience of Compassionate Use. (2007) (0)
- Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation (2015) (0)
- Comparison of PBSC Vs Cord Blood (CB) As Stem Cells Source for Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Haematological Diseases: A Single Centre Analysis. (2012) (0)
- Updates on Isatuximab in Relapsed/Refractory and Newly Diagnosed Multiple Myeloma (2022) (0)
- Genetic structure and linkage disequilibrium in African, Ameridian and quilombo remnants of Brazilian estimated by new X-STRs (2013) (0)
- Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome (2019) (0)
- Lotus 1.2.3 pour Windows (1992) (0)
- PF651 POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN A REAL LIFE SETTING: A SINGLE CENTER RETROSPECTIVE STUDY (2019) (0)
- Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial (2021) (0)
- P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) (2022) (0)
- A627 Alternate Splicing Is Frequently Observed in Myeloma and Has Impact on Clinical Outcome (2009) (0)
- Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM). (2009) (0)
- A method for HLA-G analysis by sequencing based typing (2003) (0)
- Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma (2016) (0)
- Isatuximab plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. (2022) (0)
- Association between soluble hla-g level and stages of human african trypanosomiasis (2015) (0)
- Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia (2013) (0)
- Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM) (2019) (0)
- Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy (2021) (0)
- Anti-Infectious Pathogen Specificity of Purified Monoclonal Immunoglobulins from Patients with MGUS and Multiple Myeloma (2016) (0)
- Assessment of biochemical response for multiple myeloma (MM) patients treated with Daratumumab: proposal in Cassiopeia study, IFM 2015/01 (2015) (0)
- myeloma ABT-737 is highly effective against molecular subgroups of multiple (2011) (0)
- 2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma. (2023) (0)
- Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. (2023) (0)
- A First In-Depth Analysis of Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2019) (0)
- Advancing rheumatology in the Asian Pacific region: new challenges, new horizons. Abstracts of the 15th Congress of Asia Pacific League of Associations for Rheumatology. Amman, Jordan. September 10-14, 2012. (2012) (0)
- 1.1 Genomics, genetic basis of disease, HLA/T cell recognition (2012) (0)
- OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study (2022) (0)
- 88-P: HLA-G 5' Regulatory Region and 3' Untranslated Region Variability in the Brazilian Population (2010) (0)
- New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials (2017) (0)
- Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). (2022) (0)
- Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies (2018) (0)
- [New drugs for myeloma]. (2006) (0)
- Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells (2016) (0)
- P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (0)
- Practical Management Consideration for Patients Receiving anti-CD38 Monoclonal Antibodies (2015) (0)
- Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients (2021) (0)
- MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM) (2021) (0)
- Posaconazole as Prophylaxis in Immunocompromised Patients: A Single Center Experience (2008) (0)
- Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2015) (0)
- Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS(TM) Trial (MM-010) (2015) (0)
- ACCESS TO EARLY CLINICAL TRIALS IN OLDER PATIENTS IN FRANCE: AN ANALYSIS OF THE EGALICAN 2 STUDY (2019) (0)
- Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM) (2017) (0)
- Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma (2021) (0)
- Phase III Studies Published by the IFM (Intergroupe Francophone du Myélome) (2009) (0)
- Osteonecrosis of the Jaw in Multiple Myeloma Patients (the IFM Registry). (2007) (0)
- CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients (2022) (0)
- Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial (2013) (0)
- Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma (2014) (0)
- Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy (2021) (0)
- Subgroup Analysis by Prior Treatment of the Efficacy and Safety of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the PANORAMA 1 Study (2015) (0)
- University of Southern Denmark Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma (2021) (0)
- Optimal sequencing in the management of relapsed/refractory myeloma patients (2018) (0)
- Regulation and modulation of classical HLA class I gene transcription in trophoblast cells and choriocarcinoma JEG-3 cells (1997) (0)
- The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing (2016) (0)
- Immunomodulation by Lymphodepletion and Donor Lymphocyte Infusion to Treat Post Allogeneic Transplantation Relapse (2010) (0)
- P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma (2021) (0)
- P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial (2021) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients (2020) (0)
- Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. (2023) (0)
- Jean-Louis Ferrary (1948-2020) (2021) (0)
- P-243: Subgroup analyses from the LocoMMotion study of real-life current standard of care (SOC) in patients with relapsed/refractory multiple myeloma (RRMM) (2022) (0)
- Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications (2018) (0)
- Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study (2023) (0)
- PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA (2011) (0)
- Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03) (2023) (0)
- Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases (2018) (0)
- Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT) (2010) (0)
- A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus (2014) (0)
- P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) (2022) (0)
- Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma. (2008) (0)
- Selection of HLA-G expressing tumors, can be treated by anticancer agents, and their uses (1999) (0)
- Long-term complications of total body irradiation from a cohort of 186 patients (1998) (0)
- Analysis of the genomic lanscape of multiple myeloma highlights novel candidate prognostic markers and disease subgroups (2017) (0)
- [Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia]. (1994) (0)
- Abstract B16: The pro-apoptotic effect of dexamethasone mediated by GILZ and Bim up-regulation is related to genetic heterogeneity of multiple myeloma. (2015) (0)
- Allogeneic H ematopoietic S tem-Cell T ransplantation A fter Nonmyeloablative P reparative R egimens: I mpact o f Pretransplantati on a nd P osttransplantat ion F actors on O utcome (2001) (0)
- OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study (2021) (0)
- Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemias and Leukemic Stem Cells: Therapeutic Implications (2015) (0)
- Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A. (2021) (0)
- Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153] (2022) (0)
- ElotuzumabinCombinationWithLenalidomideandLow-Dose DexamethasoneinRelapsedorRefractoryMultipleMyeloma (2012) (0)
- Comparison of MRI and 18F-FDG PET for Evaluation of the Response to Treatment of Patients Diagnosed with Multiple Myeloma: A Prospective Clinical Study (2012) (0)
- Is GvHD after allogeneic bone marrow transplantation linked to any HLA DR or DP antigens (1992) (0)
- MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. (2022) (0)
- PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (2019) (0)
- The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement (2022) (0)
- FDG PET for staging and therapeutic evaluation in patients with plasmocytoma (2007) (0)
- P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE (2022) (0)
- Gentranscripte of MHC class I HLA-G and their uses (1995) (0)
- P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (0)
- An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma (2023) (0)
- A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma (2023) (0)
- Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study (2020) (0)
- Soluble hla-g containing compositions for the treatment of inflammatory skin diseases (2000) (0)
- Prognostic Value of Cytogenetics in Patients with Acute Myeloid Leukemia Aged More Than 60 Years at Diagnosis: Identification of Subgroups Taking Benefit from Intensive Chemotherapy. Results from a Large Single Center Retrospective Study. (2007) (0)
- Transcriptional regulation of the HLA-G gene: Cell specific nuclear factors bind to a 5′ regulatory element located at 1.1 kb to the translation site of HLA-G gene (1997) (0)
- Logic programming reveals alteration of key transcription factors in multiple myeloma (2017) (0)
- Poster: MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma (2022) (0)
- Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide (2014) (0)
- randomized multicenter study mitoxantrone and cytarabine for the treatment of acute leukemias: a Combination of quinine as a potential reversing agent with (2011) (0)
- Time to Improve Bortezomib and Lenalidomide Lines of Therapy (2017) (0)
- Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM) (2016) (0)
- Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2007) (0)
- Plasma Cell Proliferation Using Ki67 Antigen Expression Defines Subgroups Related to Short Survival in Multiple Myeloma Especially with Low Beta-2 Microglobulin. (2006) (0)
- Allogeneic Stem Cell Transplantation with Reduced Intensity Conditionning Regimen (RIC) for Adult Patients with AML: Same Results in Secondary and De Novo AML. (2006) (0)
- Tandem Autologous Stem Cell Transplantation Following High Dose Chemotherapy for Transformed Low Grade and Refractory High Grade Lymphoma. (2004) (0)
- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide (2019) (0)
- Deciphering the chronology of copy number alterations in Multiple Myeloma (2018) (0)
- In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors (2022) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT). (2009) (0)
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma (2019) (0)
- Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study (2020) (0)
- 16S rRNA Gene Pyrosequencing Reveals Shift in Patient Faecal Microbiota During High-Dose Chemotherapy as Conditioning Regimen for Bone Marrow Transplantation (2014) (0)
- Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, (2011) (0)
- Clonal Chromosomal Abnormalities in Philadelphia Negative Cells during Dasatinib Treatment in Five Patients with Chronic Myeloid Leukemia. (2006) (0)
- S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM (2019) (0)
- TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1 (2022) (0)
- No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide (2018) (0)
- The Genomic Landscape of Multiple Myeloma Complex Structural Variations (2017) (0)
- POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS (2020) (0)
- OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis (2022) (0)
- Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients (2014) (0)
- Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age. (2009) (0)
- High Grade Non-Hodgkin’s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis. (2006) (0)
- 18F-FDG PET/CT in multiple myeloma: critical insights and future directions (2019) (0)
- Mitoxantrone/Cytarabine with or without Quinine as a Potential MDR- Reversing Agent for the Treatment of Acute Leukemias (1996) (0)
- P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma (2022) (0)
- ASCT for Multiple Myeloma: The Role of the Novel Agents (2014) (0)
- PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON (2022) (0)
- Results from a Meta-Analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice in Patients with Relapsed or Refractory Multiple Myeloma (2022) (0)
- The SV40 72 Base Pair Repeat: An Amazing Enhancer of Eukaryotic Gene Expression (1983) (0)
- Response Assignment Using Hevylite Correlates With Clinical Outcome in Multiple Myeloma (2017) (0)
- PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE (2019) (0)
- Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) (2021) (0)
- P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER (2022) (0)
- Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study (2023) (0)
- A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Ghvd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft (2021) (0)
- University of Southern Denmark Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
- Comparison of Efficacy and Safety of Treatment with Ofloxacin-Piperacillin and Amikacin-Piperacillin in Immunodepressed Febrile Neutropenic Patients (2012) (0)
- Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis, (2011) (0)
- RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormalmyeloma cells independently of the p53 pathway (2014) (0)
- Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant (2019) (0)
- P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS (2022) (0)
- Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies (2021) (0)
- Timing the initiation of multiple myeloma (2020) (0)
- Relative Stability Of Plasma Cells Immunophenotype In Multiple Myeloma Over Time (2013) (0)
- P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma (2021) (0)
- receiving high-dose therapy 2-microglobulin produce a powerful myeloma staging system for patients β Chromosome 13 abnormalities identified by FISH analysis and serum (2013) (0)
- 2218 Salvage extended field irradiation in disseminated follicular non-Hodgkin's lymphoma (NHL) after failure of chemotherapy (1999) (0)
- P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS (2022) (0)
- Peripheral Blood Stem Cell Grafts Mobilized by G-CSF and Plerixafor in Comparison to G-CSF Alone: Phenotypic and Functional Characterization, (2011) (0)
- P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma (2022) (0)
- Molecular Prognosis in Multiple Myeloma: The IFM Experience. (2006) (0)
- Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016) (2016) (0)
- The Brigetio Inscription CIL, III, 4346 (CLE, 440) (2003) (0)
- A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2011) (0)
- Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease (2021) (0)
- Syddansk Universitet Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
- Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study (2018) (0)
- Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (2020) (0)
- Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply (2021) (0)
- Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (2022) (0)
- Windows 3.1 (1992) (0)
- Pro-Inflammatory State of MGUS and Myeloma Patients Presenting with a Monoclonal Immunoglobulin Specific for an Infectious Pathogen (2017) (0)
- Effect of Age on Outcomes With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the STRATUSTM Trial (MM-010), A Single-Arm, Phase 3b Study (2015) (0)
- Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03 (2022) (0)
- Plasmacytoid Dendritic Cells (PDC) and Th17 Immune Response Contribution in Skin Acute Graft-Versus-Host-Disease (GVHD) (2011) (0)
- Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA (2021) (0)
- MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) (2021) (0)
- P134: ROLE OF AIRE GENE (AUTOIMMUNE REGULATOR) IN TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATION OF HLA-G (2014) (0)
- Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study. (2023) (0)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (0)
- What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort (2022) (0)
- Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone (2019) (0)
- Serum free light chain changes offer a more accurate assessment of response to therapy than urine Bence Jones protein excretion measurements in multiple myeloma (2015) (0)
- Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. (2023) (0)
- Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis (2013) (0)
- of the Intergroupe Francophone du Myélome Genetic abnormalities and survival in multiple myeloma: the experience (2011) (0)
- Designing orientation maps accessible to visually impaired people (2016) (0)
- Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study (2022) (0)
- Allogeneic stem cell transplantation (Contra) (2008) (0)
- Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier (2015) (0)
- Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma (2017) (0)
- Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM). (2012) (0)
- A628 MicroRNA Profile Identifies Distinct Clinically Relevant Subgroups in Multiple Myeloma (2009) (0)
- Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis (2018) (0)
- PCN16 Design and Rationale of the Multiple Myeloma Preamble Study: A Prospective, Non-Interventional, Multi-Center Cohort Study (2012) (0)
- P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY (2022) (0)
- Reaching Beyond Overall Response in Patients With Multiple Myeloma (2015) (0)
- Rome: The Invisible Children of Incest (2010) (0)
- S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 (2022) (0)
- Catulle et l'inceste. Approches psychanalytique et anthropologique (2002) (0)
- Book reviews (2006) (0)
- P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY (2022) (0)
- [Diabetic children and adolescents: psychological points of view]. (1986) (0)
- Excel 5 Windows (1994) (0)
- Towards the design of a quick and universal questionnaire to assess the intuitiveness of products (2021) (0)
- P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY (2022) (0)
- B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (2022) (0)
- 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma (2018) (0)
- P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY (2022) (0)
- P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT (2022) (0)
- Cicero, Espistulae ad Familiares, I, 9, 15: A Memorial of Catiline’s Conspiracy? (2007) (0)
- Jasper Griffin, Latin Poets and Roman Life, Londres, Duckworth, 1985, XIV- 226 p. (1988) (0)
- Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment (2017) (0)
- Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation (2021) (0)
- Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies. (2009) (0)
- S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST? (2019) (0)
- Expressed fusion gene landscape and its impact in multiple myeloma (2017) (0)
- Simian Virus40LatePromoter Region AbletoInitiate SimianVirus 40EarlyGeneTranscription intheAbsenceoftheSimianVirus40 Origin Sequence (1984) (0)
- Myeloma in Martinique; Characteristics and Overall Survival (2014) (0)
- P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY (2022) (0)
- High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. (2023) (0)
- ONTINUING EDUCATION PROGRAM : FOCUS . . . ultiple myeloma imaging (2013) (0)
- Microenvironment and Immunology Bioactivity and Prognostic Signi fi cance of Growth Differentiation Factor GDF 15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma (2012) (0)
- Comparison of the clinical sensitivity of two free light chain assays in a cohort of light chain multiple myeloma patients (2015) (0)
- Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study (2019) (0)
- A051 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT (2009) (0)
- G2MARS a collaborative approach to improve fodder quality of European sorghum germplasm (2018) (0)
- Differentially Associated with DNA Repair Gene Polymorphisms Patients with Systemic Sclerosis Present Increased DNA Damage (0)
- MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma (2019) (0)
- The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis (2018) (0)
- Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma. (2023) (0)
- Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma. (2014) (0)
- [Immunologic aspects of bone marrow transplantation]. (1993) (0)
- Fluorescence I n S itu H ybridization o n P eripheral-Blood Specimens I s a R eliable M ethod t o E valuate C ytogenetic Response i n C hronic M yeloid L eukemia (2000) (0)
- Donor Lymphocyte Infusions (DLI) for the Treatment of Disease Relapse in Hematological Malignancies Following Allogeneic Transplantation: Similar Efficacy Following RIC or Myeloablative Regimen (2008) (0)
- Growth through an Autocrine IGF-1 Loop IL-21 Stimulates Human Myeloma Cell (2008) (0)
- A415 RIC allo-SCT for Patients with High-Risk Myeloma: A Survey from the SFGM-TC (2009) (0)
- A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis (2016) (0)
- The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma (2019) (0)
- Factors Predicting Allogeneic Peripheral Blood Stem Cell (PBSC) Mobilization After G-CSF Treatment in Healthy Donors (2009) (0)
- Reduced Intensity Conditioning Allogeneic Stem cell Transplantation (RIC-alloSCT) for Elderly Acute Myeloid Leukaemia (AML) Patients Over 60 Years: A “donor” Versus “no donor” Comparison (2012) (0)
- Reply to J.C. Regelink et al (2010) (0)
- Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible (2020) (0)
- Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma (2021) (0)
- RIC alloSCT in MM: a long way to go. (2011) (0)
- Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies (2019) (0)
- Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma (2015) (0)
- New Strategy for Allogeneic Peripheral Blood Stem Cell Transplantation After Reduced Intensity Conditioning in Multiple Myeloma: Interim Analysis of the IFM2005-03 Study. (2009) (0)
- P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA (2022) (0)
- Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax (2022) (0)
- MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis. (2022) (0)
- How I Treat How I treat extramedullary myeloma (2016) (0)
- Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients (2022) (0)
- 5-Azacytidine (5-AZA) Salvage Therapy for Very High Risk Acute Myeloid Leukemia (AML): Response After 3 Cycles Is the Major Determinant for Outcome. (2009) (0)
- Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France (2017) (0)
- Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM (2016) (0)
- Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). (2019) (0)
- Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study (2022) (0)
- New Perspectives in Imaging Techniques (2021) (0)
- Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse (2017) (0)
- Phase 1/2 study of car fi lzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma (2015) (0)
- Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. (2023) (0)
- P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT (2022) (0)
- Sergio Castagnetti, Le „leges libitinariae“ flegree. Edizione e commento, Napoli (Satura Editrice) 2012. (2018) (0)
- Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma (2010) (0)
- Transcripts of the HLA-G gene of the major histocompatibility complex (MHC) class 1, and their applications (1995) (0)
- MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Frontline therapy of multiple myeloma (2015) (0)
- P-259: Ciltacabtagene autoleucel (cilta-cel) versus real world clinical practice in triple-class exposed multiple myeloma: adjusted comparison of patient reported outcomes from CARTITUDE-1 and LocoMMotion (2022) (0)
- The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability? (2014) (0)
- P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (2022) (0)
- BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics (2014) (0)
- Long-Lasting HHV-6 Reactivation and Immune Recovery In Adult Long-Survivors After Umbilical Cord Blood (UCB) Allo-SCT: A Comparison With PBSC As Stem-Cell Source (2013) (0)
- Use of compositions containing soluble forms of HLA-G in the treatment of inflammatory diseases of the skin, and process for obtaining them (1999) (0)
- GVHD Prophylaxis with Cyclosporine + Mycophenolate Mofetil Improves Outcome Compared to Cyclosporine Alone in Patients Receiving Reduced Intensity Conditioning Hematopoietic Stem-Cell Transplantation from Unrelated Donor for Hematological Diseases. (2007) (0)
- [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. (2021) (0)
- P047 HLA-G and HLA-E variable sites are associated with susceptibility to P. falciparum malaria in beninese toffin children (2019) (0)
- In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5 (2008) (0)
- Survival Outcomes in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the MM 003 Trial: Impact of Stable Disease (SD) as a Response to Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) (2015) (0)
- P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL (2022) (0)
- Impact of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT). (2008) (0)
- The role of PBSCT in treatment of AL amyloidosis is far from settled (2016) (0)
- Un second cas rapporté d’infection humaine à Streptococcus equi subsp. ruminatorum (2011) (0)
- The p53 Reactivating Drug PRIMA-1Met Induces Apoptosis Of Myeloma Cells Via ROS Production (2013) (0)
- PS1046 FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA (2019) (0)
- Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma (2022) (0)
- 209-P: Linkage disequilibrium between the HLA-G locus and neighbouring HLA loci (2009) (0)
- Impact Of Cyclosporine A (CsA) Concentration On The Incidence Of Severe Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2009) (0)
- Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study (2015) (0)
- Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome (2008) (0)
- PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL (2019) (0)
- Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4] (2022) (0)
- Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases (2020) (0)
- Löslische hla-g containing zusammensetsungen for treating inflammatory skin diseases (2000) (0)
- P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX (2022) (0)
- Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity. (2004) (0)
- DESCAR-T, le registre national des patients traités par CAR-T Cells (2021) (0)
- Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis. (2013) (0)
- Genomic patterns of progression in smoldering multiple myeloma (2018) (0)
- Abstracts of the Data Management GroupEBMT 2010 (2010) (0)
- Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies (2012) (0)
- Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study (2018) (0)
- Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop (2010) (0)
- Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) (2010) (0)
- OAB-054: Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma (2022) (0)
- Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS (2023) (0)
- Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. (2021) (0)
- Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients (2016) (0)
- Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (2022) (0)
- Human leukocyte antigen (HLA)-F and -G gene polymorphisms and haplotypes are associated with malaria susceptibility in the Beninese Toffin children. (2021) (0)
- Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison (2019) (0)
- Supériorité confirmée de l’association melphalan-prednisone–thalidomide (MP–T) chez des patients de plus de 75 ans avec un myélome multiple (MM) de novo : protocole IFM 01/01, MP–T versus MP en double insu versus placebo (2008) (0)
- Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry (2023) (0)
- Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) (2012) (0)
- Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire. (2009) (0)
- [Autologous peripheral blood selected CD34+ cell transplantation in the treatment of multiple myeloma]. (2001) (0)
- autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
- Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma (2023) (0)
- Word 2010 - Initiation (2011) (0)
- Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
- Switches of tyrosine‐kinase inhibitors in chronic phase of chronic myeloid leukemia in real life (2018) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. (2012) (0)
- Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine (2021) (0)
- Escalated lymphodepletion Followed by Donor Lymphocyte Infusion (DLI) can Induce a Graft-Versus-Host Response without Overwhelming Toxicity. (2009) (0)
- Growth Differentation Factor 15 Is a Survival Factor for multiple myeloma cells and its plasma Concentration In Patients Is Related to Reduced Survival (2010) (0)
- Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. (2023) (0)
- Is the MELR a good test to predict the occurrence of acute GvHD in bone marrow transplantation between genotypic HLA-identical pairs? (1991) (0)
- The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma (2019) (0)
- Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching (2020) (0)
- Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen (2019) (0)
- O431 – Influence of donors/recipients HLA-C disparity in 110 unrelated bone marrow transplantation (1996) (0)
- A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients (2019) (0)
- Reply to G. R. Mohyuddin et al and A. Garfall et al. (2021) (0)
- [Post-transplantation of Hodgkin's disease. Clinico-pathologic study of 3 cases]. (1996) (0)
- Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases (2015) (0)
- Abstract8.6-02 Genomic HLA class II typing (DR, DQ and DP specificities), primary mixed lymphocytes reaction and G.V.H. disease: Retrospective study of 41 allogeneic marrow transplantations (1989) (0)
- Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults (2014) (0)
- The chronological order of copy number changes in hyperdiploid multiple myeloma patients (2018) (0)
- Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials. (2016) (0)
- Mylotarg 9 mg/m² Combined with Intermediate Dose Aracytin and Mitoxantrone (MIDAM) in Relapsed/Refractory CD33+ Acute Myeloid Leukemia: A Single Center Phase II Experience. (2004) (0)
- Combined modality treatment and adjuvant lumbo-splenic radiotherapy (RT) in supra-diaphragmatic (SD) clinical stage (CS) I–II Hodgkin disease (HD) results in decreased rates of infra-diaphragmatic (ID) nodal relapses (R) (1997) (0)
- 6178 2 8 J U N E 2 0 1 2 I V O L U M E 1 1 9 , N U M B E R 2 6 Blood (0)
- Early Thimerosal Exposure and Neuropsychological Outcomes (2008) (0)
- CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages (2018) (0)
- Alleles and haplotypes of the 3 untranslated region of the HLA-G gene are associated with type 1 diabetes mellitus (2012) (0)
- Abstract 793: Preclinical study of efficacy and specificity of p53-reactivating drugs in multiple myeloma, identification of biomarkers. (2013) (0)
- Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome (2015) (0)
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting (2018) (0)
- Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study. (2015) (0)
- OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival (2022) (0)
- Drug Combinations with Transplantation for Myeloma. (2017) (0)
- Short title : Association of HLA-G*0106 with pregnancy diseases Summary sentence : HLA-G*0106 allele frequency is enhanced in placentas from pregnancy diseases such as pre-eclampsia and miscarriage Keywords and Topic Category : HLA-G, polymorphism, placenta, pregnancy disease. (2008) (0)
- A120 Osteonecrosis of the Jaw in Multiple Myeloma Patients: Risk Factors of Early ONJ, Decreased Impact After 2005 (2009) (0)
- The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability (2021) (0)
- Hematopoietic cell transplantation in multiple myeloma (2004) (0)
- PS1405 USE OF POMALIDOMIDE-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN FOUR EUROPEAN COUNTRIES – FINDINGS FROM PREAMBLE (2019) (0)
- Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM (2019) (0)
- Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection (2019) (0)
- Outcome After 9/10 Mismatched Unrelated Donor or Cord Blood Cells Allogeneic Stem Cell Transplantation (allo-SCT) in the Setting of Reduced-Intensity Conditioning (RIC) (2012) (0)
- 998PDManagement of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX (2017) (0)
- Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy (2013) (0)
- Sensitivity to venetoclax: the B-side of myeloma? (2021) (0)
- Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement (2023) (0)
- MM-071 Subcutaneous (SC) Isatuximab (Isa) Administration by an On-Body Delivery System (OBDS) in Combination With Pomalidomide-Dexamethasone (Pd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients: Interim Phase 1b Study Results. (2022) (0)
- P-239: Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life standard of care (SOC) treatments: results from the LocoMMotion study (2022) (0)
- Communications on multiple myeloma (2009) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin (ATG) Compared to Fludarabine and Low Dose Total Body Irradiation (TBI) for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Patients with Lymphoid Malignancies. (2010) (0)
- Genetics of autoimmunity (PP-018) (2010) (0)
- Reply to A. Gratwohl (2011) (0)
- PS1350 STRONG PRE-CLINICAL RATIONAL FOR THE USE OF MCL1/BCL2 BH3 MIMETIC COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 MIMETIC ALONE (2019) (0)
- Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study (2022) (0)
- Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma (2019) (0)
- Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) (2015) (0)
- DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma (2020) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients Running title : GWAS in multiple myeloma pharmacogenomics (2016) (0)
- Impact of oxygen content on characteristics of mesenchymal stem cells isolated from Wharton's jelly (2012) (0)
- FLT 3 ligand plasma levels in acute myeloid leukemia (2019) (0)
- Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK (2013) (0)
- Mise au point sur les indications du G-CSF pégylé (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Philippe Moreau?
Philippe Moreau is affiliated with the following schools:
